IP Library › Granted Patent US 12,624,105
Granted Patent B2
US 12,624,105 · App. 18/470,745 · Granted May 12, 2026

Chimeric antigen and t cell receptors and methods of use

Inventors: Arianne Perez (Woodland Hills, CA); Stuart A. Sievers (Van Nuys, CA); Ruben Alvarez Rodriguez (Los Angeles, CA); Jonathan Belk (Lebanon, NH); Jed Wiltzius (Woodland Hills, CA)
Assignee: Kite Pharma, Inc.
C07K16/2803A61K40/11A61K40/31A61K40/4211A61K40/4221A61P35/00C07K16/2887C07K16/2896C12N5/0636C12N5/10C12N15/63A61K2039/505A61K2239/29A61K2239/31A61K2239/38C07K2317/24C07K2317/56C07K2317/565C07K2317/622C07K2317/73C07K2317/76
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,624,105
App. No.
18/470,745
Granted
May 12, 2026
Kind
B2
Abstract

Provided is a chimeric antigen receptor (CAR) or a T cell receptor (TCR) comprising one or more of the antigen binding motifs disclosed herein. Aspects of the disclosure relate to a polynucleotide encoding a chimeric antigen receptor (CAR) or a T cell receptor (TCR) comprising one or more of the antigen binding motifs. Provided are antibodies and antigen binding systems that comprise a binding motif that binds CD20 and optionally a binding motif that binds CD19, and methods of producing and using the same. Antibodies and antigen binding systems of the present disclosure comprise CARs that comprise an anti-CD20 binding motif and an anti-CD19 binding motif. Provided are compositions, such as antibodies and CARs that are or comprise an anti-CD20/anti-CD19 antigen binding system of the present disclosure, and cell therapies comprising the same, are useful, e.g., in the treatment of cancer.

Claims (80)

1 . A method for treating a B cell cancer, comprising administering to the subject cells expressing a chimeric antigen receptor comprising an antibody or antigen binding fragment thereof having binding specificity to CD20, wherein the antibody or antigen binding fragment thereof comprises a heavy chain variable domain (VH) comprising complementarity determining regions HCDR1, HCDR2 and HCDR3, and a light chain variable domain (VL) comprising complementarity determining regions LCDR1, LCDR2 and LCDR3, wherein:

(i) the HCDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 3-5; the HCDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 6-8; the HCDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 9-11; the LCDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 14-16; the LCDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 17-19; and the LCDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 20-22;

(ii) the HCDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 25-27; the HCDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 28-30; the HCDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 31-33; the LCDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 36-38; the LCDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 39-41; and the LCDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 42-44;

(iii) the HCDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 47-49; the HCDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 50-52; the HCDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 53-55; the LCDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 58-60; the LCDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 61-63; and the LCDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 64-66;

(iv) the HCDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 69-71; the HCDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 72-74; the HCDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 75-77; the LCDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 80-82; the LCDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 83-85; and the LCDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 86-88;

(v) the HCDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 91-93; the HCDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 94-96; the HCDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 97-99; the LCDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 102-104; the LCDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 105-107; and the LCDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 108-110;

(vi) the HCDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 113-115; the HCDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 116-118; the HCDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 119-121; the LCDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 124-126; the LCDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 127-129; and the LCDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOS: 130-132;

(vii) the HCDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 135-137; the HCDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 138-140; the HCDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 141-143; the LCDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 146-148; the LCDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 149-151; and the LCDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOS: 152-154;

(viii) the HCDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 157-159; the HCDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 160-162; the HCDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 163-165; the LCDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 168-170; the LCDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 171-173; and the LCDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 174-176;

(ix) the HCDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 179-181; the HCDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 182-184; the HCDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 185-187; the LCDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 190-192; the LCDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 193-195; and the LCDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 196-198; or

(x) the HCDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 201-203; the HCDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 204-206; the HCDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 207-209; the LCDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 212-214; the LCDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 215-217; and the LCDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 218-220.

2 . The method of claim 1 , wherein:

(i) the HCDR1 comprises the amino acid of SEQ ID NO: 3; the HCDR2 comprises the amino acid of SEQ ID NO: 6; the HCDR3 comprises the amino acid of SEQ ID NO: 9; the LCDR1 comprises the amino acid of SEQ ID NO: 14; the LCDR2 comprises the amino acid of SEQ ID NO: 17; and the LCDR3 comprises the amino acid of SEQ ID NO: 20;

(ii) the HCDR1 comprises the amino acid of SEQ ID NO: 25; the HCDR2 comprises the amino acid of SEQ ID NO: 28; the HCDR3 comprises the amino acid of SEQ ID NO: 31; the LCDR1 comprises the amino acid of SEQ ID NO: 36; the LCDR2 comprises the amino acid of SEQ ID NO: 39; and the LCDR3 comprises the amino acid of SEQ ID NO: 42;

(iii) the HCDR1 comprises the amino acid of SEQ ID NO: 47; the HCDR2 comprises the amino acid of SEQ ID NO: 50; the HCDR3 comprises the amino acid of SEQ ID NO: 53; the LCDR1 comprises the amino acid of SEQ ID NO: 58; the LCDR2 comprises the amino acid of SEQ ID NO: 61; and the LCDR3 comprises the amino acid of SEQ ID NO: 64;

(iv) the HCDR1 comprises the amino acid of SEQ ID NO: 69; the HCDR2 comprises the amino acid of SEQ ID NO: 72; the HCDR3 comprises the amino acid of SEQ ID NO: 75; the LCDR1 comprises the amino acid of SEQ ID NO: 80; the LCDR2 comprises the amino acid of SEQ ID NO: 83; and the LCDR3 comprises the amino acid of SEQ ID NO: 86;

(v) the HCDR1 comprises the amino acid of SEQ ID NO: 91; the HCDR2 comprises the amino acid of SEQ ID NO: 94; the HCDR3 comprises the amino acid of SEQ ID NO: 97; the LCDR1 comprises the amino acid of SEQ ID NO: 102; the LCDR2 comprises the amino acid of SEQ ID NO: 105; and the LCDR3 comprises the amino acid of SEQ ID NO: 108;

(vi) the HCDR1 comprises the amino acid of SEQ ID NO: 113; the HCDR2 comprises the amino acid of SEQ ID NO: 116; the HCDR3 comprises the amino acid of SEQ ID NO: 119;

the LCDR1 comprises the amino acid of SEQ ID NO: 124; the LCDR2 comprises the amino acid of SEQ ID NO: 127; and the LCDR3 comprises the amino acid of SEQ ID NO: 130;

(vii) the HCDR1 comprises the amino acid of SEQ ID NO: 135; the HCDR2 comprises the amino acid of SEQ ID NO: 138; the HCDR3 comprises the amino acid of SEQ ID NO: 141; the LCDR1 comprises the amino acid of SEQ ID NO: 146; the LCDR2 comprises the amino acid of SEQ ID NO: 149; and the LCDR3 comprises the amino acid of SEQ ID NO: 152;

(viii) the HCDR1 comprises the amino acid of SEQ ID NO: 157; the HCDR2 comprises the amino acid of SEQ ID NO: 160; the HCDR3 comprises the amino acid of SEQ ID NO: 163; the LCDR1 comprises the amino acid of SEQ ID NO: 168; the LCDR2 comprises the amino acid of SEQ ID NO: 171; and the LCDR3 comprises the amino acid of SEQ ID NO: 174;

(ix) the HCDR1 comprises the amino acid of SEQ ID NO: 179; the HCDR2 comprises the amino acid of SEQ ID NO: 182; the HCDR3 comprises the amino acid of SEQ ID NO: 185; the LCDR1 comprises the amino acid of SEQ ID NO: 190; the LCDR2 comprises the amino acid of SEQ ID NO: 193; and the LCDR3 comprises the amino acid of SEQ ID NO: 196; or

(x) the HCDR1 comprises the amino acid of SEQ ID NO: 201; the HCDR2 comprises the amino acid of SEQ ID NO: 204; the HCDR3 comprises the amino acid of SEQ ID NO: 207; the LCDR1 comprises the amino acid of SEQ ID NO: 212; the LCDR2 comprises the amino acid of SEQ ID NO: 215; and the LCDR3 comprises the amino acid of SEQ ID NO: 218.

3 . The method of claim 1 , wherein:

(i) the HCDR1 comprises the amino acid of SEQ ID NO: 4; the HCDR2 comprises the amino acid of SEQ ID NO: 7; the HCDR3 comprises the amino acid of SEQ ID NO: 10; the LCDR1 comprises the amino acid of SEQ ID NO: 15; the LCDR2 comprises the amino acid of SEQ ID NO: 18; and the LCDR3 comprises the amino acid of SEQ ID NO: 21;

(ii) the HCDR1 comprises the amino acid of SEQ ID NO: 26; the HCDR2 comprises the amino acid of SEQ ID NO: 29; the HCDR3 comprises the amino acid of SEQ ID NO: 32; the LCDR1 comprises the amino acid of SEQ ID NO: 37; the LCDR2 comprises the amino acid of SEQ ID NO: 40; and the LCDR3 comprises the amino acid of SEQ ID NO: 43;

(iii) the HCDR1 comprises the amino acid of SEQ ID NO: 48; the HCDR2 comprises the amino acid of SEQ ID NO: 51; the HCDR3 comprises the amino acid of SEQ ID NO: 54; the LCDR1 comprises the amino acid of SEQ ID NO: 59; the LCDR2 comprises the amino acid of SEQ ID NO: 62; and the LCDR3 comprises the amino acid of SEQ ID NO: 65;

(iv) the HCDR1 comprises the amino acid of SEQ ID NO: 70; the HCDR2 comprises the amino acid of SEQ ID NO: 73; the HCDR3 comprises the amino acid of SEQ ID NO: 76; the LCDR1 comprises the amino acid of SEQ ID NO: 81; the LCDR2 comprises the amino acid of SEQ ID NO: 84; and the LCDR3 comprises the amino acid of SEQ ID NO: 87;

(v) the HCDR1 comprises the amino acid of SEQ ID NO: 92; the HCDR2 comprises the amino acid of SEQ ID NO: 95; the HCDR3 comprises the amino acid of SEQ ID NO: 98; the LCDR1 comprises the amino acid of SEQ ID NO: 103; the LCDR2 comprises the amino acid of SEQ ID NO: 106; and the LCDR3 comprises the amino acid of SEQ ID NO: 109;

(vi) the HCDR1 comprises the amino acid of SEQ ID NO: 114; the HCDR2 comprises the amino acid of SEQ ID NO: 117; the HCDR3 comprises the amino acid of SEQ ID NO: 120; the LCDR1 comprises the amino acid of SEQ ID NO: 125; the LCDR2 comprises the amino acid of SEQ ID NO: 128; and the LCDR3 comprises the amino acid of SEQ ID NO: 131;

(vii) the HCDR1 comprises the amino acid of SEQ ID NO: 136; the HCDR2 comprises the amino acid of SEQ ID NO: 139; the HCDR3 comprises the amino acid of SEQ ID NO: 142; the LCDR1 comprises the amino acid of SEQ ID NO: 147; the LCDR2 comprises the amino acid of SEQ ID NO: 150; and the LCDR3 comprises the amino acid of SEQ ID NO: 153;

(viii) the HCDR1 comprises the amino acid of SEQ ID NO: 158; the HCDR2 comprises the amino acid of SEQ ID NO: 161; the HCDR3 comprises the amino acid of SEQ ID NO: 164; the LCDR1 comprises the amino acid of SEQ ID NO: 169; the LCDR2 comprises the amino acid of SEQ ID NO: 172; and the LCDR3 comprises the amino acid of SEQ ID NO: 175;

(ix) the HCDR1 comprises the amino acid of SEQ ID NO: 180; the HCDR2 comprises the amino acid of SEQ ID NO: 183; the HCDR3 comprises the amino acid of SEQ ID NO: 186; the LCDR1 comprises the amino acid of SEQ ID NO: 191; the LCDR2 comprises the amino acid of SEQ ID NO: 194; and the LCDR3 comprises the amino acid of SEQ ID NO: 197; or

(x) the HCDR1 comprises the amino acid of SEQ ID NO: 202; the HCDR2 comprises the amino acid of SEQ ID NO: 205; the HCDR3 comprises the amino acid of SEQ ID NO: 208; the LCDR1 comprises the amino acid of SEQ ID NO: 213; the LCDR2 comprises the amino acid of SEQ ID NO: 216; and the LCDR3 comprises the amino acid of SEQ ID NO: 219.

4 . The method of claim 1 , wherein:

(i) the HCDR1 comprises the amino acid of SEQ ID NO: 5; the HCDR2 comprises the amino acid of SEQ ID NO: 8; the HCDR3 comprises the amino acid of SEQ ID NO: 11; the LCDR1 comprises the amino acid of SEQ ID NO: 16; the LCDR2 comprises the amino acid of SEQ ID NO: 19; and the LCDR3 comprises the amino acid of SEQ ID NO: 22;

(ii) the HCDR1 comprises the amino acid of SEQ ID NO: 27; the HCDR2 comprises the amino acid of SEQ ID NO: 30; the HCDR3 comprises the amino acid of SEQ ID NO: 33; the LCDR1 comprises the amino acid of SEQ ID NO: 38; the LCDR2 comprises the amino acid of SEQ ID NO: 41; and the LCDR3 comprises the amino acid of SEQ ID NO: 44;

(iii) the HCDR1 comprises the amino acid of SEQ ID NO: 49; the HCDR2 comprises the amino acid of SEQ ID NO: 52; the HCDR3 comprises the amino acid of SEQ ID NO: 55; the LCDR1 comprises the amino acid of SEQ ID NO: 60; the LCDR2 comprises the amino acid of SEQ ID NO: 63; and the LCDR3 comprises the amino acid of SEQ ID NO: 66;

(iv) the HCDR1 comprises the amino acid of SEQ ID NO: 71; the HCDR2 comprises the amino acid of SEQ ID NO: 74; the HCDR3 comprises the amino acid of SEQ ID NO: 77; the LCDR1 comprises the amino acid of SEQ ID NO: 82; the LCDR2 comprises the amino acid of SEQ ID NO: 85; and the LCDR3 comprises the amino acid of SEQ ID NO: 88;

(v) the HCDR1 comprises the amino acid of SEQ ID NO: 93; the HCDR2 comprises the amino acid of SEQ ID NO: 96; the HCDR3 comprises the amino acid of SEQ ID NO: 99; the LCDR1 comprises the amino acid of SEQ ID NO: 104; the LCDR2 comprises the amino acid of SEQ ID NO: 107; and the LCDR3 comprises the amino acid of SEQ ID NO: 110;

(vi) the HCDR1 comprises the amino acid of SEQ ID NO: 115; the HCDR2 comprises the amino acid of SEQ ID NO: 118; the HCDR3 comprises the amino acid of SEQ ID NO: 121; the LCDR1 comprises the amino acid of SEQ ID NO: 126; the LCDR2 comprises the amino acid of SEQ ID NO: 129; and the LCDR3 comprises the amino acid of SEQ ID NO: 132;

(vii) the HCDR1 comprises the amino acid of SEQ ID NO: 137; the HCDR2 comprises the amino acid of SEQ ID NO: 140; the HCDR3 comprises the amino acid of SEQ ID NO: 143; the LCDR1 comprises the amino acid of SEQ ID NO: 148; the LCDR2 comprises the amino acid of SEQ ID NO: 151; and the LCDR3 comprises the amino acid of SEQ ID NO: 154;

(viii) the HCDR1 comprises the amino acid of SEQ ID NO: 159; the HCDR2 comprises the amino acid of SEQ ID NO: 162; the HCDR3 comprises the amino acid of SEQ ID NO: 165; the LCDR1 comprises the amino acid of SEQ ID NO: 170; the LCDR2 comprises the amino acid of SEQ ID NO: 173; and the LCDR3 comprises the amino acid of SEQ ID NO: 176;

(ix) the HCDR1 comprises the amino acid of SEQ ID NO: 181; the HCDR2 comprises the amino acid of SEQ ID NO: 184; the HCDR3 comprises the amino acid of SEQ ID NO: 187; the LCDR1 comprises the amino acid of SEQ ID NO: 192; the LCDR2 comprises the amino acid of SEQ ID NO: 195; and the LCDR3 comprises the amino acid of SEQ ID NO: 198; or

(x) the HCDR1 comprises the amino acid of SEQ ID NO: 203; the HCDR2 comprises the amino acid of SEQ ID NO: 206; the HCDR3 comprises the amino acid of SEQ ID NO: 209; the LCDR1 comprises the amino acid of SEQ ID NO: 214; the LCDR2 comprises the amino acid of SEQ ID NO: 217; and the LCDR3 comprises the amino acid of SEQ ID NO: 220.

5 . The method of claim 1 , wherein:

(i) the VH comprises the amino acid sequence of SEQ ID NO: 1 and the VL comprises the amino acid sequence of SEQ ID NO: 12;

(ii) the VH comprises the amino acid sequence of SEQ ID NO: 23 and the VL comprises the amino acid sequence of SEQ ID NO: 34;

(iii) the VH comprises the amino acid sequence of SEQ ID NO: 45 and the VL comprises the amino acid sequence of SEQ ID NO: 56;

(iv) the VH comprises the amino acid sequence of SEQ ID NO: 67 and the VL comprises the amino acid sequence of SEQ ID NO: 78;

(v) the VH comprises the amino acid sequence of SEQ ID NO: 89 and the VL comprises the amino acid sequence of SEQ ID NO: 100;

(vi) the VH comprises the amino acid sequence of SEQ ID NO: 111 and the VL comprises the amino acid sequence of SEQ ID NO: 122;

(vii) the VH comprises the amino acid sequence of SEQ ID NO: 133 and the VL comprises the amino acid sequence of SEQ ID NO: 144;

(viii) the VH comprises the amino acid sequence of SEQ ID NO: 155 and the VL comprises the amino acid sequence of SEQ ID NO: 166;

(ix) the VH comprises the amino acid sequence of SEQ ID NO: 177 and the VL comprises the amino acid sequence of SEQ ID NO: 188; or

(x) the VH comprises the amino acid sequence of SEQ ID NO: 199 and the VL comprises the amino acid sequence of SEQ ID NO: 210.

6 . The method of claim 1 , wherein:

(i) the heavy chain variable domain is at least 80% identical to SEQ ID NO: 1 and the light chain variable domain is at least 80% identical to SEQ ID NO: 12;

(ii) the heavy chain variable domain is at least 80% identical to SEQ ID NO: 23 and the light chain variable domain is at least 80% identical to SEQ ID NO: 34;

(iii) the heavy chain variable domain is at least 80% identical to SEQ ID NO: 45 and the light chain variable domain is at least 80% identical to SEQ ID NO: 56;

(iv) the heavy chain variable domain is at least 80% identical to SEQ ID NO: 67 and the light chain variable domain is at least 80% identical to SEQ ID NO: 78;

(v) the heavy chain variable domain is at least 80% identical to SEQ ID NO: 89 and the light chain variable domain is at least 80% identical to SEQ ID NO: 100;

(vi) the heavy chain variable domain is at least 80% identical to SEQ ID NO: 111 and the light chain variable domain is at least 80% identical to SEQ ID NO: 122;

(vii) the heavy chain variable domain is at least 80% identical to SEQ ID NO: 133 and the light chain variable domain is at least 80% identical to SEQ ID NO: 144;

(viii) the heavy chain variable domain is at least 80% identical to SEQ ID NO: 155 and the light chain variable domain is at least 80% identical to SEQ ID NO: 166;

(ix) the heavy chain variable domain is at least 80% identical to SEQ ID NO: 177 and the light chain variable domain is at least 80% identical to SEQ ID NO: 188; or

(x) the heavy chain variable domain is at least 80% identical to SEQ ID NO: 199 and the light chain variable domain is at least 80% identical to SEQ ID NO: 210.

7 . The method of claim 1 , wherein the antigen binding fragment is a single chain fragment (scFv).

8 . The method of claim 1 , wherein the cells further comprise a second chimeric antigen receptor that comprises a binding motif that specifically binds an antigen selected from the group consisting of 5T4, alpha-fetoprotein, B cell maturation antigen (BCMA), B cell receptor, CA-125, carcinoembryonic antigen, CD19, CD20, CD22, CD23, CD30, CD33, CD40, CD56, CD79, CD78, CD123, CD138, c-Met, CSPG4, IgM, C-type lectin-like molecule 1 (CLL-1), EGFRvIII, epithelial tumor antigen, ERBB2, FLT3, folate binding protein, GD2, GD3, HER1-HER2 in combination, HER2-HER3 in combination, HER2/Neu, HERV-K, HIV-1 envelope glycoprotein gp41, HIV-1 envelope glycoprotein gp120, IL-11Ralpha, kappa chain, lambda chain, melanoma-associated antigen, mesothelin, MUC-1, mutated p53, mutated ras, prostate-specific antigen, ROR1, VEGFR2, EphA3 (EPH receptor A3), BAFFR (B-cell activating factor receptor), and combinations thereof.

9 . The method of claim 8 , wherein the binding motif is an anti-CD19 binding motif.

10 . The method of claim 9 , wherein the anti-CD19 binding motif comprises a heavy chain variable domain (VH) comprising complementarity determining regions HCDR1 comprising the amino acid sequence of SEQ ID NO: 224, HCDR2 comprising the amino acid sequence of SEQ ID NO: 227 and HCDR3 comprising the amino acid sequence of SEQ ID NO: 230, and a light chain variable domain (VL) comprising complementarity determining regions LCDR1 comprising the amino acid sequence of SEQ ID NO: 235, LCDR2 comprising the amino acid sequence of SEQ ID NO: 238 and LCDR3 comprising the amino acid sequence of SEQ ID NO: 241.

11 . The method of claim 10 , wherein the VH of the anti-CD19 binding motif comprises the amino acid sequence of SEQ ID NO: 221 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 221, and the VL of the anti-CD19 binding motif comprises the amino acid sequence of SEQ ID NO: 232 or an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 232.

12 . The method of claim 9 , wherein the anti-CD19 binding motif is a single chain fragment (scFv).

13 . The method of claim 12 , wherein the second chimeric antigen receptor further comprises a transmembrane domain that is a transmembrane domain of 4-1BB/CD137, an alpha chain of a T cell receptor, a beta chain of a T cell receptor, CD3 epsilon, CD4, CD5, CD8 alpha, CD9, CD16, CD19, CD22, CD28, CD33, CD37, CD45, CD64, CD80, CD86, CD134, CD137, CD154, or a zeta chain of a T cell receptor, or any combination thereof.

14 . The method of claim 1 , wherein the cells are CAR-T cells.

15 . The method of claim 14 , wherein the CAR-T cells are allogeneic CAR-T cells.

16 . The method of claim 14 , wherein the CAR-T cells are autologous CAR-T cells.

17 . The method of claim 1 , wherein the B cell cancer is acute lymphoblastic leukemia (ALL), non T cell ALL, acute myeloid leukemia, B cell prolymphocytic leukemia, B cell acute lymphoid leukemia (“BALL”), blastic plasmacytoid dendritic cell neoplasm, Burkitt's lymphoma, chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), chronic myeloid leukemia, chronic or acute leukemia, diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), Hodgkin's Disease, malignant lymphoproliferative conditions, MALT lymphoma, Marginal zone lymphoma, monoclonal gammapathy of undetermined significance (MGUS), myelodysplasia and myelodysplastic syndrome, non-Hodgkin's lymphoma (NHL), plasma cell proliferative disorder, (asymptomatic myeloma, smoldering multiple myeloma, indolent myeloma, plasmablastic lymphoma, plasmacytoid dendritic cell neoplasm, plasmacytomas, (plasma cell dyscrasia, solitary myeloma, solitary plasmacytoma, extramedullary plasmacytoma, multiple plasmacytoma, POEMS syndrome (also known as Crow-Fukase syndrome; Takatsuki disease; and PEP syndrome), small cell- or a large cell-follicular lymphoma, splenic marginal zone lymphoma (SMZL), systemic amyloid light chain amyloidosis, T cell acute lymphoid leukemia (“TALL”), T cell lymphoma, Waldenstrom macroglobulinemia, Mantle cell lymphoma (MCL), Transformed follicular lymphoma (TFL), Primary mediastinal B cell lymphoma (PMBCL), Multiple myeloma, Hairy cell lymphoma/leukemia, or a combination thereof.

18 . The method of claim 1 , wherein the B cell cancer is diffuse large B cell lymphoma (DLBCL).

19 . The method of claim 1 , wherein the B cell cancer is relapsed or refractory diffuse large B cell lymphoma (DLBCL).

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 29, 2025
From: ADIMAB, LLC
To: KITE PHARMA, INC.
Reel/Frame 070973/0804 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 29, 2025
From: PEREZ, ARIANNE; SIEVERS, STUART A.; RODRIGUEZ, RUBEN ALVAREZ
To: KITE PHARMA, INC.
Reel/Frame 070973/0832 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 29, 2025
From: BELK, JONATHAN
To: ADIMAB, LLC
Reel/Frame 070973/0759 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 29, 2025
From: WILTZIUS, JED
To: KITE PHARMA, INC.
Reel/Frame 070973/0884 →
Continuity (3)
Division 16711180 · Dec 11, 2019
Provisional Application 62778893 · Dec 12, 2018
Related Publication 20240115611A1 · Apr 11, 2024
References Cited (386)
US 4946778A · Ladner et al. · 1990 [cited by applicant]
US 5091513A · Huston et al. · 1992 [cited by applicant]
US 5132405A · Huston et al. · 1992 [cited by applicant]
US 5545806A · Lonberg et al. · 1996 [cited by applicant]
US 5545807A · Surani et al. · 1996 [cited by applicant]
US 5569825A · Lonberg et al. · 1996 [cited by applicant]
US 5591827A · Brakenhoff et al. · 1997 [cited by applicant]
US 5625126A · Lonberg et al. · 1997 [cited by applicant]
US 5633425A · Lonberg et al. · 1997 [cited by applicant]
US 5661016A · Lonberg et al. · 1997 [cited by applicant]
US 5728388A · Terman · 1998 [cited by applicant]
US 5827642A · Riddell et al. · 1998 [cited by applicant]
US 5830462A · Crabtree et al. · 1998 [cited by applicant]
US 5834266A · Crabtree et al. · 1998 [cited by applicant]
US 5869337A · Crabtree et al. · 1999 [cited by applicant]
US 6040177A · Riddell et al. · 2000 [cited by applicant]
US 6165787A · Crabtree et al. · 2000 [cited by applicant]
US 6319494B1 · Capon et al. · 2001 [cited by applicant]
US 6410319B1 · Raubitschek et al. · 2002 [cited by applicant]
US 6797514B2 · Berenson et al. · 2004 [cited by applicant]
US 6867041B2 · Berenson et al. · 2005 [cited by applicant]
US 6905874B2 · Berenson et al. · 2005 [cited by applicant]
US 7709226B2 · Foote · 2010 [cited by applicant]
US 7741465B1 · Eshhar et al. · 2010 [cited by applicant]
US 8211422B2 · Eshhar et al. · 2012 [cited by applicant]
US 8486693B2 · Park et al. · 2013 [cited by applicant]
US 8562991B2 · Igawa et al. · 2013 [cited by applicant]
US 8679492B2 · Blein et al. · 2014 [cited by applicant]
US 9296820B2 · Umana et al. · 2016 [cited by applicant]
US 9834590B2 · Campana et al. · 2017 [cited by applicant]
US 9855298B2 · Bot et al. · 2018 [cited by applicant]
US 9987308B2 · Riddell et al. · 2018 [cited by applicant]
US 10221245B2 · Brogdon et al. · 2019 [cited by applicant]
US 10287350B2 · Kochenderfer · 2019 [cited by applicant]
US 10493139B2 · Wu et al. · 2019 [cited by applicant]
US 11723923B2 · Perez et al. · 2023 [cited by applicant]
US 11793834B2 · Perez et al. · 2023 [cited by applicant]
US 20020006409A1 · Wood · 2002 [cited by applicant]
US 20040126363A1 · Jensen et al. · 2004 [cited by applicant]
US 20070014720A1 · Gazit-bornstein et al. · 2007 [cited by applicant]
US 20100104509A1 · King et al. · 2010 [cited by applicant]
US 20110286980A1 · Brenner · 2011 [cited by applicant]
US 20120093842A1 · Eshhar et al. · 2012 [cited by applicant]
US 20120130076A1 · Holt et al. · 2012 [cited by applicant]
US 20120213783A1 · Rosenberg et al. · 2012 [cited by applicant]
US 20130266551A1 · Campana et al. · 2013 [cited by applicant]
US 20130287748A1 · June et al. · 2013 [cited by applicant]
US 20140050708A1 · Powell et al. · 2014 [cited by applicant]
US 20140099309A1 · Powell, Jr. et al. · 2014 [cited by applicant]
US 20140134195A1 · Russell · 2014 [cited by applicant]
US 20140154228A1 · Volk et al. · 2014 [cited by applicant]
US 20140171649A1 · Li et al. · 2014 [cited by applicant]
US 20140227237A1 · June et al. · 2014 [cited by applicant]
US 20140271635A1 · Brogdon et al. · 2014 [cited by applicant]
US 20140286934A1 · Blein et al. · 2014 [cited by applicant]
US 20140286987A1 · Spencer et al. · 2014 [cited by applicant]
US 20150038684A1 · Jensen · 2015 [cited by applicant]
US 20150202286A1 · June et al. · 2015 [cited by applicant]
US 20150266973A1 · Jarjour et al. · 2015 [cited by applicant]
US 20150283178A1 · June et al. · 2015 [cited by applicant]
US 20150344844A1 · Better et al. · 2015 [cited by applicant]
US 20160009813A1 · Themeli et al. · 2016 [cited by applicant]
US 20160046700A1 · Foster et al. · 2016 [cited by applicant]
US 20170173080A1 · Lee et al. · 2017 [cited by applicant]
US 20170368098A1 · Chen et al. · 2017 [cited by applicant]
US 20180355052A1 · Orentas et al. · 2018 [cited by applicant]
US 20180371093A1 · Bilic et al. · 2018 [cited by applicant]
US 20190119638A1 · Sadelain et al. · 2019 [cited by applicant]
US 20190151361A1 · Wiezorek · 2019 [cited by applicant]
US 20190358262A1 · Albertson · 2019 [cited by applicant]
US 20190359697A1 · Young et al. · 2019 [cited by applicant]
US 20190388471A1 · June et al. · 2019 [cited by applicant]
US 20200002400A1 · Yao et al. · 2020 [cited by applicant]
US 20200283729A1 · Loew et al. · 2020 [cited by applicant]
US 20210145304A1 · Visweswara et al. · 2021 [cited by applicant]
US 20210147569A1 · Press et al. · 2021 [cited by applicant]
US 20210161959A1 · Bot et al. · 2021 [cited by applicant]
US 20220160729A1 · Deisher · 2022 [cited by applicant]
US 20220281976A1 · Rosenthal et al. · 2022 [cited by applicant]
US 20220387492A1 · Bot et al. · 2022 [cited by applicant]
US 20220389449A1 · Paul et al. · 2022 [cited by applicant]
US 20230255962A1 · Boiko et al. · 2023 [cited by applicant]
US 20230374105A1 · Bitter et al. · 2023 [cited by applicant]
US 20240018256A1 · Chen et al. · 2024 [cited by applicant]
US 20240058381A1 · Wiezorek · 2024 [cited by applicant]
US 20240082307A1 · Bot et al. · 2024 [cited by applicant]
US 20240252538A1 · Brannetti et al. · 2024 [cited by applicant]
US 20240279665A1 · Zhao et al. · 2024 [cited by applicant]
US 20250002579A1 · Cooper et al. · 2025 [cited by applicant]
US 20250145707A1 · Perez et al. · 2025 [cited by applicant]
CN 103820393 · 2014 [cited by applicant]
CN 106701827 · 2017 [cited by applicant]
CN 108384760A · 2018 [cited by applicant]
WO WO9715669 · 1997 [cited by applicant]
WO WO2007002223 · 2007 [cited by applicant]
WO WO2006130458 · 2007 [cited by applicant]
WO WO2008081035 · 2008 [cited by applicant]
WO WO2009091826 · 2009 [cited by applicant]
WO WO2009054863 · 2009 [cited by applicant]
WO WO2010095031 · 2010 [cited by applicant]
WO WO2012033885 · 2012 [cited by applicant]
WO WO2012079000 · 2012 [cited by applicant]
WO WO2012129514 · 2012 [cited by applicant]
WO WO2012138475 · 2012 [cited by applicant]
WO WO2013123061 · 2013 [cited by applicant]
WO WO2013154760 · 2013 [cited by applicant]
WO WO2014055657 · 2014 [cited by applicant]
WO WO2014127261 · 2014 [cited by applicant]
WO WO2014153270 · 2014 [cited by applicant]
WO WO2014184744 · 2014 [cited by applicant]
WO WO2014186469 · 2014 [cited by applicant]
WO WO2015075468 · 2015 [cited by applicant]
WO WO2015080981 · 2015 [cited by applicant]
WO WO2015090229 · 2015 [cited by applicant]
WO 2015120096A2 · 2015 [cited by applicant]
WO WO2015123642 · 2015 [cited by applicant]
WO WO2015142675 · 2015 [cited by applicant]
WO WO2015187528 · 2015 [cited by applicant]
WO WO2016033570 · 2016 [cited by applicant]
WO WO2016044745 · 2016 [cited by applicant]
WO WO2016069282 · 2016 [cited by applicant]
WO WO2016090369 · 2016 [cited by applicant]
WO WO2016100232 · 2016 [cited by applicant]
WO WO2016164731 · 2016 [cited by applicant]
WO WO2016191755 · 2016 [cited by applicant]
WO WO2016191756 · 2016 [cited by applicant]
WO WO2016201389 · 2016 [cited by applicant]
WO WO2016210293 · 2016 [cited by applicant]
WO WO2017015783 · 2017 [cited by applicant]
WO WO2017025038 · 2017 [cited by applicant]
WO WO2017070395 · 2017 [cited by applicant]
WO WO2017161353 · 2017 [cited by applicant]
WO WO2017189959 · 2017 [cited by applicant]
WO 2017222593A1 · 2017 [cited by applicant]
WO WO2018067992 · 2018 [cited by applicant]
WO WO2018102786 · 2018 [cited by applicant]
WO WO2018145648 · 2018 [cited by applicant]
WO WO2018161017 · 2018 [cited by applicant]
WO WO2018183927 · 2018 [cited by applicant]
WO WO2018213337 · 2018 [cited by applicant]
WO WO2019058348 · 2019 [cited by applicant]
WO WO2019079564 · 2019 [cited by applicant]
WO WO2021092290 · 2021 [cited by applicant]
WO WO2015157252 · 2025 [cited by applicant]
Bodogai et al. Anti-CD20 Antibody Promotes Cancer Escape via Enrichment of Tumor-Evoked Regulatory B Cells Expressing Low Levels of CD20 and CD137L. Cancer Res 73(7): 2127-2138, 2013. [cited by examiner]
Casan et al. Anti-CD20 monoclonal antibodies: reviewing a revolution. Human Vaccines Immunother 14(12): 2820-2841, 2018. [cited by examiner]
Cho et al. Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma. Antibodies 6: 18, 2017, doi: 10.3390/antibod6040018 (22 total pages). [cited by examiner]
Kapoor et al. Anti-CD20 monoclonal antibody therapy in multiple myeloma. Brit J Haematol 141: 135-148, 2008. [cited by examiner]
Mangogna et al. Rituximab Plus Chemotherapy Provides No Clinical Benefit in a Peripheral T-Cell Lymphoma not Otherwise Specified with Aberrant Expression of CD20 and CD79a: A Case Report and Review of the Literature. Di… [cited by examiner]
Salles et al. Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience. Adv Ther 34: 2232-2273, 2017. [cited by examiner]
White et al. Cancer Prevention for the Next Generation. J Adolesc Health 52: S1-S7, 2013. [cited by examiner]
Zhao et al. Universal CARs, universal T cells, and universal CAR T cells. J Hematol Oncol 11: 132, 2018 (9 total pages). [cited by examiner]
Al-Lazikani et al., “Standard conformations for the canonical structures of immunoglobulins” J Mol Bioi 273: 927-948 (1997). [cited by applicant]
Akbar et al., “A compact vocabulary of paratope-epitope interactions enables predictability of antibody-antigen binding,” Cell Reports, 34 pp. 1-21 (Year: 2021). [cited by applicant]
Albanza et al., “Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions is Affected by Hinge and Transmembrane Domains,” Mol. Ther., 25(11), 2452-2465 (Epub Jul. 27, 2017). [cited by applicant]
Ando et al., A Safeguard System for Induced Pluripotent Stem Cell-Derived Rejuvenated T Cell Therapy, Stem Cell Reports 2015, vol. 5, pp. 597-608. [cited by applicant]
Arnon et al., “Monoclonal Antibodies and Cancer Therapy”, pp. 243-256, Alan R. Liss, Inc. (1985). [cited by applicant]
Barbas et al., “Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro”, Proc. Natl. Acad. Sci. USA, 89(19): 9339-43 (1992). [cited by applicant]
Beatty et al., “Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce antitumor activity in solid malignancies,” Cancer Immunology Research, 2(2), 112-120 (2014). [cited by applicant]
Brentjens et al., “CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia,” ScienceTranslational Medicine, 5(177), 177ra38 (2013), 19 pages, Author … [cited by applicant]
Brentjens et al., “Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by COBO and interleukin-15,” Nature Medicine, 9(3), 279-286 (2003). [cited by applicant]
Brentjens et al., “Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts,” Clinical Cancer Research, 13(18), 5426-5435 (2007). [cited by applicant]
Brentjens et al., “Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen,” Hematology. American Society of Hematology. Education Program, 2012, 143-151 (2012). [cited by applicant]
Brentjens et al., “Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias,” Blood, 118 (18), 4817-4828 (2011). [cited by applicant]
Brudno et al., “Clinical anti-lymphoma activity and toxicity of T cells expressing a novel anti-CD19 chimeric antigen receptor with fully-human variable regions,” ASCO Meeting Library, abstract cited in J Clin Oncol., 3… [cited by applicant]
Brudno et al., “Toxicities of Chimeric Antigen Receptor T Cells: Recognition and Management,” Blood, May 20, 2016 (online), pp. 3321-3330, vol. 127, No. 26. [cited by applicant]
Burns et al., “Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and non mammalian cells,” Proc. Natl. Acad. Sci., USA,… [cited by applicant]
Cartellieri et al., Chimeric Antigen Receptor-Engineered T Cells for Immunotherapy of Cancer. Journal of Biomedicine and Biotechnology 2010, XP055206629, doi:10.1155/2010/956304. 13 pages. [cited by applicant]
Champe et al., “Monoclonal Antibodies That Block the Activity of Leukocyte Function-associated Antigen 1 Recognize Three Discrete Epitopes in the Inserted Domain of CD11a”, J Biol Chem, 270(3): 1388-94 (1995). [cited by applicant]
Chayen, “The role of oil in macromolecular crystallization”, Structure, 5(10): 1269-1274 (1997). [cited by applicant]
Cheadle et al., “Natural expression of the CD19 antigen impacts the long-term engraftment but not antitumor activity of CD19-specific engineered T cells,” Journal of Immunology, 184 (4), 1885-1896 (2010). [cited by applicant]
Chen et al., Discovery of Small-Molecule Inhibitors of HCV NS3-4A Protease as Potential Therapeutic Agents against HCV Infection. Current Medicinal Chemistry 2005, vol. 12, No. 20, doi:10.2174/0929867054864769, pp. 2317… [cited by applicant]
Cheung et al., “Epitope-specific antibody response to the surface antigen of duck hepatitis B virus in infected ducks”, Virology 176(2): 546-552 (1990). [cited by applicant]
Chothia et al., “Canonical structures for the hypervariable regions of immunoglobulins”, J Mol Biol, 196: 901-917 (1987). [cited by applicant]
Chothia et al., “Structural repertoire of the human VH segments” J Mol Biol, 227: 799-817 (1992). [cited by applicant]
Cole et al., In: “Monoclonal Antibodies and Cancer Therapy”, Alan R. Liss, Inc., pp. 77-96 (1985). [cited by applicant]
Cooper et al., “T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect,” Blood, 101 (4), 1637-1644 (2003). [cited by applicant]
Cote et al., Generation of human monoclonal antibodies reactive with cellular antigens, Proc Natl Acad Sci USA, 80 (7): 2026-2030 (1983). [cited by applicant]
Cunningham et al., “High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis”, Science 244(4908): 1081-85 (1989). [cited by applicant]
Dayhoff et al., “Atlas of Protein Sequence and Structure: A Model of Evolutionary Change in Proteins”, 5: 345-352 (1978). [cited by applicant]
Devereux et al., “A comprehensive set of sequence analysis programs for the VAX”, Nucl. Acid Res., 12: 387-395 (1984). [cited by applicant]
Eshhar et al., “Tumor-specific T-bodies: towards clinical application”, Cancer Immunol Immunotherapy, 45(3-4): 131-136 (1997). [cited by applicant]
Examination Report for Australian Application No. 2019397033 dated Mar. 9, 2023. 5 pages. [cited by applicant]
Examiner Requisition for Canadian Application No. 3, 122,762 dated Jul. 29, 2022. 4 pages. [cited by applicant]
Fegan et al. “Chemically controlled protein assembly: techniques and applications”, Chem. Rev., 110(6): 3315-3336 (2010). [cited by applicant]
Finney et al., “Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product”, Journal of Immunology, 161(6): 2791-2797 (1998). [cited by applicant]
First Examination Report dated Sep. 2, 2021 in GCC Appl. No. GC 2019-38820. [cited by applicant]
Fishwild et al., “High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice.” Nature Biotechnology, 14(7): 845-51 (1996). [cited by applicant]
Galon et al., Characterization of anti-CD19 chimeric antigen receptor (CAR) T cell-mediated tumor microenvironment immune gene profile in a multicenter trial (ZUMA-1) with axicabtagene ciloleucel (axi-cel, KTE-C19). J. … [cited by applicant]
Gen Bank Accession No. ADM64594.1, published Jun. 11, 2012. [cited by applicant]
Giege et al., “Crystallogenesis of biological macromolecules: facts and perspectives”, Acta Crystallogr D Biol Crystallogr, 50(Pt 4): 339-350 (1994). [cited by applicant]
Gross et al., “Therapeutic Potential of T Cell Chimeric Antigen Receptors (CARs) in Cancer Treatment: Counteracting Off-Tumor Toxicities for Safe CART Cell Therapy”, Annu. Rev. Pharmacol. Toxicol., 56: 59-83 (2016). [cited by applicant]
Grupp et al., “Chimeric antigen receptor-modified T cells for acute lymphoid leukemia,” New England Journal of Medicine, 368 (16), 1509-1518 (2013). [cited by applicant]
Gust et al., Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells. Cancer Discovery 2017, 7(12), pp. 1404-1419. [cited by applicant]
Hellstrom et al., “Antibodies For Drug Delivery”, in Controlled Drug Delivery (2nd Ed.), Robinson et al. (eds.), Marcel Dekker, Inc., 623-53 (1987). [cited by applicant]
Henikoff et al., “Amino acid substitution matrices from protein blocks”, Proc. Natl. Acad. Sci. U.S.A., 89(22): 10915-10919 (1992). [cited by applicant]
Hermans et al., “The vital assay: a versatile fluorometric technique for assessing CTL- and NKT-mediated cytotoxicity against multiple targets in vitro and in vivo,” Journal of Immunological Methods, 285 (1), 25-40 (200… [cited by applicant]
Hombach et al., “Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28-OX40 signalling,” International Journal of Cancer, 129 (12), 2935-2944 (2011). [cited by applicant]
Hoogenboom et al., By-passing immunisation: Human antibodies from synthetic repertoires of germline VH gene segments rearranged in vitro, J. Mol. Biol., 227(2): 381-388 (1991). [cited by applicant]
Huston et al., “Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2019/065776 dated Jun. 24, 2020. 21 pages. [cited by applicant]
Jena et al., Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood 2010; vol. 116, No. 7, pp. 1035-1044, XP055021403. [cited by applicant]
Jensen et al., “Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans,” Biology of Blood and Marrow Tr… [cited by applicant]
Kabat et al., “Attempts to locate complementarity-determining residues in the variable positions of light and heavy chains”, Ann NY Acad Sci, 190: 382-391 (1971). [cited by applicant]
Kalos et al., T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia, Sci. Transl. Med., 3(95): 95ra73 (2011). [cited by applicant]
Kirkland et al., “Analysis of the fine specificity and cross-reactivity of monoclonal anti-lipid A antibodies”, J. Immunol. 137(11): 3614-3619 (1986). [cited by applicant]
Kochenderfer et al., “B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells,” Blood, 119(12), 2709-2720 (2012… [cited by applicant]
Kochenderfer et al., “Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor”, J. Clin… [cited by applicant]
Kochenderfer et al., “Construction and Pre-clinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor”, J Immunother., 32(7): 689-702 (2009). [cited by applicant]
Kochenderfer et al., “Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19,” Blood, 116 (20), 4099-4102 (2010). [cited by applicant]
Kochenderfer et al., “Treating B-cell cancers with T cells expressing anti CD19 chimeric antigen receptors,” Nature Reviews. Clinical Oncology, 10(5), 267-276 (2013). [cited by applicant]
Kozbor et al., “The production of monoclonal antibodies from human lymphocytes”, Immunol Today, 4(3): 72-9 (1983). [cited by applicant]
Krause et al., “Antigen-dependent CD28 Signaling Selectively Enhances Survival and Proliferation in Genetically Modified Activated Human Primary T Lymphocytes”, J. Exp. Med., 188(4): 619-626 (1998). [cited by applicant]
Lamers et al., “Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells,” Blood, 117 (1), 72-82 (2011). [cited by applicant]
Latza et al., “The human OX40 homolog: cDNA structure, expression and chromosomal assignment of the ACT35 antigen,” European Journal of Immunology, 24 (3), 677-683 (1994). [cited by applicant]
Lee et al., Current concepts in the diagnosis and management of cytokine release syndrome, Blood 2014, 124(2): pp. 188-195. [cited by applicant]
Ling et al., “Advances in cancer immunotherapy based on chimeric antigen receptor,” Translational Med. J., 4 (3), 97-104 (2015). [cited by applicant]
Lippow et al., “Computational design of antibody-affinity improvement beyond in vivo maturation,” Nature Biotechnology, 25(10) pp. 1171-1176. (Year: 2007). [cited by applicant]
Littman et al., The isolation and sequence of the gene encoding T8: A molecule defining functional classes of T lymphocytes, Cell 1985, vol. 40, pp. 237-246. [cited by applicant]
Lo et al., “Conformational epitope matching and prediction,” BMC Genomics, 22(Suppl 2) pp. 1-16 (Year: 2021). [cited by applicant]
Locke et al., “Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma”, Molecular Therapy, pp. 285-295, vol. 25, No. 1 (2017). [cited by applicant]
Locke et al., Abstract CT019: Primary results from ZUMA-1: a pivotal trial of axicabtagene ciloleucel (axicel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (NHL). AACR Annual Meeting 2017. 4 page… [cited by applicant]
Locke et al., Updated Phase 1 Results from ZUMA-1: Molecular Therapy, vol. 24, Supplement 1, (Year: 2016). 1 page. [cited by applicant]
Lonberg et al. “Human antibodies from transgenic mice”, Intern. Rev. Immunol., 13(1) 65-93 (1995). [cited by applicant]
Lonberg et al., “Antigen-specific human antibodies from mice comprising four distinct genetic modifications”, Nature, 368(6474): 856-859 (1994). [cited by applicant]
Lu et al., “A Rapid Cell Expansion Process for Production of Engineered Autologous CAR-T Cell Therapies”, Human Gene Therapy Methods, pp. 209-218, vol. 27, No. 6. (2016). [cited by applicant]
Mannering et al., “A sensitive method for detecting proliferation of rare autoantigen-specific human T cells,” Journal of Immunological Methods, 283 (1-2), 173-183 (2003). [cited by applicant]
Marks et al., “By-passing immunization. Human antibodies from V-gene libraries displayed on phage”, J. Mol. Biol., 22(3):581-97 (1991). [cited by applicant]
Marks et al., “By-passing immunization: building high affinity human antibodies by chain shuffling”, Biotechnology, 10(7):779-783 (1992). [cited by applicant]
McPherson, “Crystallization of Proteins from Polyethylene Glycol”, J Biol Chem, 251 (20): 6300-6303 (1976). [cited by applicant]
McPherson, “Current approaches to macromolecular crystallization”, Eur J Biochem, 189: 1-23 (1990). [cited by applicant]
Moldenhauer et al., Identity of HML-1 Antigen on Intestinal Intraepithelial T Cells and of B-Iy7 Antigen on Hairy Cell Leukaemia, Scandinavian Journal of Immunology, 32(2): 77-82 (1990). [cited by applicant]
Moran et al., “The TNFRs OX40, 4-1 BB, and CD40 as targets for cancer immunotherapy,” Current Opinion in Immunology, 25 (2), 230-237 (2013). [cited by applicant]
Morel et al., “Monoclonal antibodies to bovine serum albumin: affinity and specificity determinations”, Mol Immunol, 25(1): 7-15 (1988). [cited by applicant]
Morrison, “Success in specification”, Nature, 368, 812-13 (1994). [cited by applicant]
Nadler et al., “84, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes,” Journal of Immunology, 131 (1), 244-250 (1983). [cited by applicant]
Neelapu et al., “Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma”, The New England Journal of Medicine, pp. 2531-2544, vol. 377, No. 26 (2017). [cited by applicant]
Neuberger, “Generating high-avidity human Mabs in mice”, Nature Biotechnology, 14: 826 (1996). [cited by applicant]
Nicholson et al., “Construction and characterisation of a functional CD19 specific single chain Fv fragment for immunotherapy of B lineage leukaemia and lymphoma,” Molecular Immunology, 34 (16-17), 1157-1165 (1997). [cited by applicant]
Notice of Preliminary Rejection for Korean Application No. 10-2021-7021608 dated Aug. 18, 2023. 17 pages. [cited by applicant]
Ochi et al., “Functional immunoglobulin M production after transfection of cloned immunoglobulin heavy and light chain genes into lymphoid cells,” Proceedings of the National Academy of Sciences of the United States of … [cited by applicant]
Office Action and Search Report for Taiwan Application No. 110125603 dated Oct. 31, 2023. 20 pages. [cited by applicant]
Office Action for Canadian Application No. 3, 122,762 dated Sep. 18, 2023. 7 pages. [cited by applicant]
Office Action for Japanese Application No. 2021-533159 dated Jan. 10, 2023. 4 pages. [cited by applicant]
Office Action for Japanese Application No. 2021-533159 dated Jul. 5, 2022. 10 pages. [cited by applicant]
Office Action, issued in TW Application No. 108145595, dated Jan. 13, 2021. [cited by applicant]
Park et al., Adoptive Transfer of Chimeric Antigen Receptor Re-directed Cytolytic T Lymphocyte Clones in Patients with Neuroblastoma. Molecular Therapy 2007, vol. 15, No. 4, pp. 825-833. [cited by applicant]
Patel et al., T-cell killing of heterogenous tumor or viral targets with bispecific chimeric immune receptors. Cancer Gene Therapy 2000, vol. 7, No. 8, pp. 1127-1134, XP055259929. [cited by applicant]
Pinchera et al. (eds.), “Analysis, Results, And Future Prospective of The Therapeutic Use of Radiolabeled Antibody in Cancer Therapy”, in Monoclonal Antibodies For Cancer Detection And Therapy, pp. 475-506 (1985). [cited by applicant]
Porter et al., “Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia”, N. Engl. J. Med., 365(8):725-33 (2011). [cited by applicant]
Porter et al., “Comparison of efficiency of infection of human gene therapy target cells via four different retroviral receptors,” Human Gene Therapy, 7 (8),913-919 (1996). [cited by applicant]
Raboisson et al., Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350. Bioorganic & Me… [cited by applicant]
Ramos et al., “CAR-T Cell Therapy for Lymphoma,” Annu. Rev. Med. 67, pp. 165-183 (Year: 2016). [cited by applicant]
Ren et al., Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition, Clin Cancer Res; 23(9); 2255-2266. 2017. [cited by applicant]
Rosenberg et al., “Adoptive cell transfer as personalized immunotherapy for human cancer”, Cancer Immunology and Immunotherapy, 348: 62-68 (2015). [cited by applicant]
Rubio et al., “Ex vivo identification, isolation and analysis of tumor-cytolytic T cells,” Nature Medicine, 9 (11), 1377-1382 (2003). [cited by applicant]
Ruella et al., “Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You”, Curr Hematol Malig Rep, 11: 368-384 (2016). [cited by applicant]
Sadelain et al., “The Basic Principles of Chimeric Antigen Receptor Design”, Cancer Discovery, 3:388-398 (2013). [cited by applicant]
Sadelain et al., “Targeting Tumors with Genetically Enhanced T Lymphocytes”, Nature Rev. Cancer, 3: 35-45 (2003). [cited by applicant]
Savoldo et al., “CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients,” Journal of Clinical Investigation, 121 (5), 1822-1826 (2011). [cited by applicant]
Schneider et al., Minimizing leukemia escape: implementing a dual anti-CD20- and CD19-scFv- based chimeric antigen receptor (CAR). Journal for Immuno Therapy of Cancer 2015, vol. 3, No. 2, doi:10.1186/2051-1426-3-S2-P12… [cited by applicant]
Sommermeyer et al., Fully human CD19-specific chimeric antigen receptors for T-cell therapy, Leukemia 31(10): 2191-2199 (2017). [cited by applicant]
Tammana et al., 4-1BB and CD28 Signaling Plays a Synergistic Role in Redirecting Umbilical Cord Blood T Cells Against B-Cell Malignancies, Human Gene Therapy 2010 , 21, pp. 75-86. [cited by applicant]
Thorpe et al., Monoclonal antibodies '84: biological and clinical applications : Proocedings of the International Symposium on Monoclonal antibodies '84 held in Florence, Italy, Oct. 16-19, 1984. [cited by applicant]
Thorpe et al., “The preparation and cytotoxic properties of antibody-toxin conjugates”, Immunol. Rev., 62: 119-58 (1982). [cited by applicant]
Tramontano et al., “Framework residue 71 is a major determinant of the position and conformation of the second hypervariable region in the VH domains of immunoglobulins” J Mol Biol, 215(1):175-82 (1990). [cited by applicant]
Uniprot KB-P01732 (CD8A Human) (14 pages) Jul. 21, 1986. [cited by applicant]
Urbanska et al., Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells. Journal of Translational Medicine 2014, vol. 12, No. 1, XP021207565. 12 pages. [cited by applicant]
Venkatraman et al., Macrocyclic inhibitors of HCV NS3 protease. Expert Opinion on Therapeutic Patents 2009, vol. 19, No. 9, doi: 10.1517/13543770903044994, pp. 1277-1303, XP055084885. [cited by applicant]
Watkins et al., “CD19-targeted Immunotherapies for Treatment of Patients with non-Hodgkin B-cell Lymphomas”, Expert Opinion on Investigational Drugs, pp. 601-611, vol. 27, No. 7 (2018). [cited by applicant]
Weinberg et al., “Science gone translational: the OX40 agonist story,” Immunological Reviews, 244 (1), 218-231 (2011), Author Manuscript. [cited by applicant]
Wong et al., “Ab-Ligity: identifying sequence-dissimilar antibodies that bind to the same epitope,” MABS, vol. 13, No. 1 pp. 1-8 (Year: 2021). [cited by applicant]
Wu et al., “Remote control of therapeutic T cells through a small molecule-gated chimeric receptor”, Science, 350:6258 (2014). [cited by applicant]
Yang et al., “A simplified method for the clinical-scale generation of central memory-like CDS+ T cells after transduction with lentiviral vectors encoding antitumor antigen T-cell receptors,” Journal of Immunotherapy, … [cited by applicant]
Zebedee et al., “Human combinatorial antibody libraries to hepatitis B surface antigen”, Proc. Natl. Acad. Sci. USA, 89(8): 3175-79 (1992). [cited by applicant]
Highlights of Prescribing Information for ACTEMRA R (tocilizumab), 2017, 43 pages. [cited by applicant]
Highlights of Prescribing Information for YESCARTA (axicabtagene ciloleucel), 2017, 31 pages. [cited by applicant]
Jaffe et al., “Understanding the New WHO Classification of Lymphoid Malignancies: Why It's Important and How It Will Affect Practice,” American Society of Clinical Oncology, 2017, vol. 37, pp. 535-546. [cited by applicant]
Neelapu et al., “2-Year Follow-up and High-Risk Subset Analysis of Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma,” Blood, 2018, No. 132, Supplement 1, A… [cited by applicant]
Neelapu et al., “Kte-C19 (anti-CD19 Car T Cells) Induces Complete Remissions in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Pivotal Phase 2 Zuma-1,” Blood, 2016, Abstract, 128 (22) :… [cited by applicant]
Swerlow et al., “The 2016 revision of the World Health Organization classification of lymphoid neoplasms,” Blood, 2016, vol. 127, No. 20, 16 pages. [cited by applicant]
Whitlow et al., “An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability,” Protein Engineering, 1993, vol. 6, No. 8, pp. 989-995. [cited by applicant]
Yoon-Hwan, “High-grade B-cell lymphoma,” Korean Society for Laboratory Hematology News Letter, 2017, vol. 23, 3 pages. [cited by applicant]
Abramson et al., High Durable CR Rates in Relapsed/Refractory (R/R) Aggressive B-NHL Treated with the CD19-Directed Car T Cell Product JCAR017 (Transcend NHL 001): Defined Composition Allows for Dose-Finding and Definit… [cited by applicant]
Bhojwani et al. (2018), “Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia”, Leukemia, Acute lymphoblastic leukemia, accessed at https://doi.org/10.1038/s41375-018-0265-z,… [cited by applicant]
Borowitz et al. (2015), “Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232”, Blood, 126(8), 964-971. [cited by applicant]
Brudno et al., Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft… [cited by applicant]
Brudno et al., Chimeric antigen receptor T-cell therapies for lymphoma, Nature Reviews Clinical Oncology 2018, vol. 15, pp. 31-46. [cited by applicant]
BRÜGGEMANN et al. (2017), “Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation”, Blood Advances, 1(25), 2456-2466. [cited by applicant]
Cannarile et al. (2017), “Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy”, Journal for Immuno Therapy of Cancer, 5(53), 1-13. [cited by applicant]
Cao et al., Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma, Frontiers in Oncology 2019, vol. 9, article 767. [cited by applicant]
Chen et al., Anti-CD19 Chimeric Antigen Receptor T Cells Improve Responses to Chemotherapy-Refractory Mantle Cell Lymphoma: A Case Report, Blood 2016, vol. 128, No. 22: 5393, DOI: 10.1182/blood. V128.22.5393.5393. 2 pag… [cited by applicant]
Cheson et al. (2007), “Revised Response Criteria for Malignant Lymphoma”, Journal of Clinical Oncology, 25(5), 579-586. [cited by applicant]
Cheson et al. (2014), “Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification”, Journal of Clinical Oncology, 1-10. [cited by applicant]
Crotta et al. (2018), “Survival after stem-cell transplant in pediatric and young-adult patients with relapsed and refractory B-cell acute lymphoblastic leukemia”, Curr Med Resin, Opin., 34, 1-18. [cited by applicant]
Deangelo et al. (2017), “32nd Annual Meeting and Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2017): Part One,” Journal for Immuno Therapy of Cancer, 5 (Suppl 2)(86), P217. [cited by applicant]
Decision of Final Rejection for Japanese Application No. 2020-521585 dated Apr. 18, 2023. 9 pages. [cited by applicant]
Decision of Final Rejection for Japanese Application No. 2023-132752 dated Aug. 5, 2025, 4 pages. [cited by applicant]
Dolmans et al. (2003), “Photodynamic therapy for cancer”, Nature Reviews, Cancer, 3, 380-397. [cited by applicant]
Enblad et al., A Phase I/IIa Trial Using CD19-Targeted Third-Generation Car T Cells for Lymphoma and Leukemia, Clinical Cancer Research 2018, vol. 24, No. 24, pp. 6185-6194, DOI: 10.1158/1078- 0432.CCR-18-0426. [cited by applicant]
Examination Report for Australia Patent Application No. 2018351046 dated Nov. 17, 2021. 4 pages. [cited by applicant]
Examination Report for Australian Application No. 2021282551 dated Dec. 14, 2022.4 pages. [cited by applicant]
Examination Report for Australian Application No. 2021282551 dated Nov. 7, 2022. 5 pages. [cited by applicant]
Examination Report for Australian Patent Application No. 2018351046 dated Dec. 16, 2020, 5 pages. [cited by applicant]
Examination Report for Australian Patent Application No. 2020380366 dated Jun. 7, 2024. 5 pages. [cited by applicant]
Examination Report for Australian Patent Application No. 2021282551 dated Jul. 29, 2022. 5 pages. [cited by applicant]
Examination Report for Australian Patent Application No. 2021282551 dated May 9, 2022. 4 pages. [cited by applicant]
Examination Report for New Zealand Application No. 777087 dated Nov. 20, 2023. 3 pages. [cited by applicant]
Examination Report issued on Canadian application counterpart 3,084,470, mailed Mar. 23, 2021. [cited by applicant]
Final Office Action for Japanese Application No. 2023-132752 dated Feb. 12, 2025, 8 pages. [cited by applicant]
First Office Action for Mexican Application No. MX/a/2021/006968 dated Jul. 25, 2025, 17 pages. [cited by applicant]
Fraietta et al., Determinants of response and resistance to CD19 chimeric antigen receptor (Car) T cell therapy of chronic lymphocytic leukemia, Nature Medicine 2018, vol. 24, pp. 563-571. [cited by applicant]
Frey et al. (2019), “Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia”, Journal of Clinical Oncology, 1-10. [cited by applicant]
Gilead Sciences Announces Fourth Quarter and Full Year 2018 Financial Results?Gilead?Feb. 4, 2019?https://s24.q4cdn.com/804398512/files/doc_news/archive/829f46cd-0ddb-43d5-bedb-3771670d8102.pdf. [cited by applicant]
Guedan et al., “Engineering and Design of Chimeric Antigen Receptors,” Molecular Therapy: Methods & Clinical Development, 2019, vol. 12, pp. 145-156. [cited by applicant]
Gupta et al. (2018), “Flow-cytometric vs. - morphologic assessment of remission in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group (COG)”, Leukemia, Springer Nature, accessed at https… [cited by applicant]
Hamilton, “Gm-Csf as a target in inflammatory/autoimmune disease: current evidence and future therapeutic potential”, Expert Reviews, Clin. Immunol., 2015, Early online, accessed at 10.1586/1744666X.2015.1024110, 1-9. [cited by applicant]
Hay et al., Chimeric Antigen Receptor (Car) T Cells: Lessons Learned from Targeting of CD19 in B-Cell Malignancies. Drugs 2017, doi 10.1007/s40265-017-0690-8. 16 pages. [cited by applicant]
“Hematopoietic and Lymphoid Tumors—WHO Classification, 2016 Version,” Journal of Clinical Laboratory Medicine, vol. 61., No. 7, 2017, pp. 847-888. [cited by applicant]
Hirayama et al., The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 Car T cells, Blood, 2019, vol. 133, No. 17, pp. 1876-1887. [cited by applicant]
Hunger et al. (2015), “Acute Lymphoblastic Leukemia in Children”, The New England Journal of Medicine, 373(16), 1541-1552. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2018/056467 dated Apr. 21, 2020, 11 pages. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2020/059285 dated Apr. 12, 2021. 9 pages. [cited by applicant]
Jain et al. (2019), “Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management”, Annual Clinical Updates in Hematological Malignancies, 94, 710-725. [cited by applicant]
Jain et al., Axicabtagene ciloleucel (KTE-C19), an anti-CD19 Car T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin's lymphoma, Therapeutics and Clinical Risk Management 2018, vol. 14, pp. … [cited by applicant]
Juo, Pei-Show (2002) “Concise dictionary of biomedicine and molecular biology.” second edition, Library of Congress Cataloging-in-Publication Data, CRC Press, 1163. [cited by applicant]
Kantarjian et al. (2017), “Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia”, The New England Journal of Medicine, 376(9), 836-847. [cited by applicant]
Kite, A Gilead Company, “A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3)”, ClinicalTrials.go… [cited by applicant]
Klein et al., “Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties,” mAbs 5:1, pp. 22-33 (Year: 2013). [cited by applicant]
Kochenderfer et al. (2017), “Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels”, Journal of Clinical Oncology, 35(16), 1803-1813. [cited by applicant]
Kochenderfer et al., Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood. Nov. 1, 20101;116(19):3875-86. [cited by applicant]
Lackie et al. (2013) The Dictionary of Cell and Molecular Biology, 5th edition, Academic Press, 748 pages. [cited by applicant]
Larson et al., Pre-clinical development of gene modification of haematopoietic stem cells with chimeric antigen receptors for cancer immunotherapy, Human Vaccines & Immunotherapeutics 2017, vol. 13, No. 5, 1094-1104. [cited by applicant]
Lee et al. (2015), “T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial”, The Lancet, 385, 517-528. [cited by applicant]
Li et al., A good response of refractory mantel cell lymphoma to haploidentical Car T cell therapy after failure of autologous Car T cell therapy, Journal for ImmunoTherapy of Cancer 2019, vol. 7, No. 51. 7 pages. [cited by applicant]
Liu et al., Current approaches and advance in mantle cell lymphoma treatment, Stem Cell 2015, 2;18. [cited by applicant]
Martin et al., “Postibrutinib outcomes in patients with mantle cell lymphoma”, Clinical Trials and Observations, Blood, vol. 127, No. 12, Mar. 24, 2016, pp. 1559-1563. [cited by applicant]
Maude et al. (2018), “Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia”, The New England Journal of Medicine, 378(5), 439-448. [cited by applicant]
Neelapu et al. (2018), “Chimeric antigen receptor T-cell therapy assessment and management of toxicities”, Nature Reviews, Clinical Oncology, 15, 47-62. [cited by applicant]
Nguyen et al. (2008), “Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study”, Leukemia, 22, 2142-2150. [cited by applicant]
Notice of Final Rejection for Korean Application No. 10-2020-7013686 dated Oct. 6, 2022. 8 pages. [cited by applicant]
Notice of Final Rejection Korean for Patent Application No. 10-2020-7013686 dated Jun. 3, 2022. 7. [cited by applicant]
Notice of Preliminary Rejection for Korean Application No. 10-2021-7021608 dated Feb. 26, 2024. 6 pages. [cited by applicant]
Notice of Preliminary Rejection for Korean Application No. 10-2021-7021608 dated Oct. 20, 2024. 4 pages. [cited by applicant]
Notice of Preliminary Rejection for Korean Patent Application No. 10-2020-7013686 dated Oct. 14, 2021.13 pages. [cited by applicant]
Office Action and Search Report for Chinese Application No. 201880067426.5 dated Feb. 4, 2023. 13 pages. [cited by applicant]
Office Action for Canadian Application No. 3,122,762 dated Nov. 4, 2024. 3 pages. [cited by applicant]
Office Action for Canadian Application No. 3,177,829 dated Feb. 23, 2024. 5 pages. [cited by applicant]
Office Action for Canadian Patent Application No. 3,084,470 dated Mar. 23, 2022. 4 pages. [cited by applicant]
Office Action for Chinese Application No. 201980091506.9 dated Aug. 7, 2024. 15 pages. [cited by applicant]
Office Action for Chinese Application No. 201980091506.9 dated Mar. 18, 2024. 19 pages. [cited by applicant]
Office Action for Israeli Application No. 283734 dated Oct. 26, 2023. 5 pages. [cited by applicant]
Office Action for Japanese Application No. 2020-521585 dated Oct. 25, 2022. 8 pages. [cited by applicant]
Office Action with Search Report for Taiwan Application No. 107136797 dated Sep. 15, 2022. 12 Pages. [cited by applicant]
Official Action for Argentinian Patent Application No. 20180103032 dated Feb. 15, 2022. 9 pages. [cited by applicant]
Oskarsson et al. (2016), “Relapsed childhood acute lymphoblastic leukemia in the Nordic countries: prognostic factors, treatment and outcome”, Acute Lymphoblastic Leukemia, Haematologica, 101(1), 68-76. [cited by applicant]
Park et al. (2018), “Long-Term Follow-up of CD19 Car Therapy in Acute Lymphoblastic Leukemia”, The New England Journal of Medicine, 449-459. Vol. 378. [cited by applicant]
Partial Supplementary European Search Report for European Application No. 20886085.8 dated Apr. 5, 2024. 23 pages. [cited by applicant]
Penfold et al., “The FDA grants KTE-C19 Priority Review for the treatment of transplant-ineligible relapsed/refractory Non-Hodgkin Lymphoma,” LymphomaHub, 2017, 1 page. [cited by applicant]
Ruella et al., The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma, Clinical Cancer Research, 2016, 22(11):2684-2696. [cited by applicant]
Sabatino et al., “Production of Anti-CD19 Car T Cells for ZUMA-3 and -4: Phase 1/2 Multicenter Studies Evaluating KTE-C19 in Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (R/R All)”, Blood, … [cited by applicant]
Sadelain et al., “CD19 Car Therapy for Acute Lymphoblastic Leukemia,” American Society of Clinical Oncology Educational Book 2015, e360-e363. [cited by applicant]
Schrappe et al. (2012), “Outcomes after Induction Failure in Childhood Acute Lymphoblastic Leukemia”, The New England Journal of Medicine, 366(15), 1371-1381. [cited by applicant]
Schuster et al. (2019), “Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma”, The New England Journal of Medicine, 380(1), 45-56. [cited by applicant]
Schuster et al., “Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas,” The New England Journal of Medicine, 2017, vol. 377, pp. 2545-2554. [cited by applicant]
Shah et al., “High Rates of Minimal Residual Disease-Negative (MRD-) Complete Responses (CR) in Adult and Pediatric and Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R All) Treated with KTE-C19 (anti… [cited by applicant]
Shah et al., “End of phase I results of ZUMA-3, a phase 1/2 study of KTE-X19, anti-CD19 chimeric antigen receptor (Car) T cell therapy, in adult patients (pts) with relapsed/refractory (R/R) acute lymphoblastic leukemia… [cited by applicant]
Shah et al., A Phase 1 Study with Point-of-Care Manufacturing of Dual Targeted, Tandem Anti-CD19, Anti-CD20 Chimeric Antigen Receptor Modified T (Car-T) Cells for Relapsed, Refractory, Non-Hodgkin Lymphoma, Blood 2018, … [cited by applicant]
Song et al., “CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo”, Blood, 119(3): 696-706 (2012). [cited by applicant]
Sotillo et al. (2015), “Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy”, Cancer Discovery, OF1-OF14. [cited by applicant]
Stackelberg et al. (2016), “Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia”, Journal of Clinical Oncology, 34(36), 4381-4389. [cited by applicant]
Stahli et al., “Distinction of epitopes by monoclonal antibodies”, Methods in Enzymology, 92: 242-253 (1983). [cited by applicant]
Sun et al. (2018), “Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study”, Acute lymphoblastic leukemia, Springer Nature, 32, 2316… [cited by applicant]
A128 Topp et al. (2014), “Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study”, The Lancet, 16, 57- 66. [cited by applicant]
Turtle et al., Immunotherapy of non-Hodgkin lymphoma with a defined ratio of CD8+ and CD4+ CD19- specific chimeric antigen receptor-modified T cells, Science Translational Medicine 2016, vol. 8, No. 355, doi: 10. 1126/s… [cited by applicant]
Wang et al. (2017), “Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial”, The Lancet, 1-9 http://dx.doi.org/10.1016/S0140-6736 (17) 33108-2. [cited by applicant]
Wang et al. (2020), “KTE-X19 Car T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma”, The New England Journal of Medicine, 382(14), 1331-1342. [cited by applicant]
Wang et al., Safety and preliminary efficacy in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) receiving lisocabtagene maraleucel (Liso-cel) in Transcend Nhl 001, Journal of Clinical Oncology, … [cited by applicant]
Wang et al., ZUMA-2: A phase 2 multi-center study evaluating the efficacy of KTE-C19 (Anti-CD19 Car T cells) in patients with relapsed/refractory mantle cell lymphoma (R/R MCL), Annals of Oncology, 2016, vol. 27(Supplem… [cited by applicant]
Wicks et al. (2015), “Targeting GM-CSF in inflammatory diseases”, Nature Reviews, Rheumatology, 1-12. [cited by applicant]
Gore L. et al. “Survival after blinatumomab treatment in pediatric patients with relapsed/refactory B-cell precursor acute lymphoblastic leukemia”, Blood Cancer J. Aug. 2, 20182; 8(9):80. (Year 2018). [cited by applicant]
Kansagra Aj et al. “Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the (EBMT) and the (ASBMT)”, Bone Marrow Transplant. Nov. 2019; 5… [cited by applicant]
Paul S et al. “Adult-Acute Lymphoblastic Leukemia” Symposium on neoplastic hematology and medical oncology, vol. 91 Issue 11 p1645-1666 Nov. 2016 (Year 2016). [cited by applicant]
Rheingold et al. (2019), “Prognostic factors for survival after relapsed acute lymphoblastic leukemia (All): A Children's Oncology Group (COG) study”, Journal of Clinical Oncology, List of Issues, 37(15), 1-5. [cited by applicant]
Schneider et al.: “A tandem CD19/CD20 Car lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines”, Journal for Immunotherapy of Cancer, Biomed Central Ltd, London, Uk, vol. 5, No. 1,… [cited by applicant]
Zah et al.: “T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells”, Cancer Immunology Research, vol. 4, No. 6, Apr. 8, 2016 (2016-04-08), pp. 498-508, XP05529096… [cited by applicant]